Blueprint Medicines Corporation (BPMC)
Jul 18, 2025 - BPMC was delisted (reason: acquired by SNY)
129.46
0.00 (0.00%)
Inactive · Last trade price on Jul 17, 2025
Blueprint Medicines Employees
Blueprint Medicines had 649 employees as of December 31, 2024. The number of employees decreased by 6 or -0.92% compared to the previous year.
Employees
649
Change (1Y)
-6
Growth (1Y)
-0.92%
Revenue / Employee
$820,615
Profits / Employee
-$227,342
Market Cap
n/a
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 649 | -6 | -0.92% |
| Dec 31, 2023 | 655 | 14 | 2.18% |
| Dec 31, 2022 | 641 | 146 | 29.49% |
| Dec 31, 2021 | 495 | 66 | 15.38% |
| Dec 31, 2020 | 429 | 46 | 12.01% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
BPMC News
- 2 months ago - BLUEPRINT MEDICINES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Blueprint Medicines Corporation - BPMC - Business Wire
- 2 months ago - Blueprint Medicines Announces Data Reinforcing Sustained Clinical Efficacy and Well-Tolerated Safety Profile of Long-Term AYVAKIT®/AYVAKYT® (avapritinib) Treatment at 2025 EHA and EAACI Congresses - PRNewsWire
- 3 months ago - Johnson Fistel Investigates Fairness of Proposed Sale of Blueprint Medicines - GlobeNewsWire
- 3 months ago - Blueprint Medicines Soars 27% on $9.5 Billion Buyout. Why This Drug Is Key to the Deal. - Barrons
- 3 months ago - Sanofi to acquire Blueprint Medicines, expanding portfolio in rare immunological disease and adding early-stage pipeline in immunology - PRNewsWire
- 3 months ago - Sanofi buys US biopharma group Blueprint in $9.1 bln deal - Reuters
- 3 months ago - Sanofi to Acquire Blueprint Medicines for Up to $9.5 Billion - WSJ
- 3 months ago - Press Release: Sanofi to acquire Blueprint Medicines, expanding portfolio in rare immunological disease and adding early-stage pipeline in immunology - GlobeNewsWire